Skip to Main Content

Paper Details

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
Ann Intern Med
20
2022
AF, Apixaban, Atrial Fibrillation, Dabigatran, Edoxaban, GIB, ICH, Patients, Rivaroxaban, apixaban, atrial fibrillation, chronic kidney disease, dabigatran, edoxaban, gastrointestinal bleeding, intracranial hemorrhage, ischemic stroke, patients, people, rivaroxaban, systemic embolism, warfarin
Author NameAffiliation
Wallis C Y LauUniversity College London School of Pharmacy, University College London Hospitals NHS Foundation Trust, University of Hong Kong
Aroon D HingoraniInstitute of Cardiovascular Sciences, University College London, and University College London British Heart Foundation Research Accelerator
  • 1 - 2

Datasets

Release 1.2